Nikhil Ananth

Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g. chemotherapy). Learn more at www.ensoma.com.

Enzene is an innovation-driven biotech company a subsidiary of Alkem Laboratories Ltd. (one of the top five pharmaceutical companies in India*) located in Pune, India. Enzene’s focus lies in producing biosimilars, novel biologics, synthetic peptides and phytopharmaceuticals. Enzene also offers a range of biologics CDMO and CMO services with capabilities from clone development up to GMP manufacturing supported by bio-reactor capacities ranging from 20 litres to 2000 litres.

Learn more at enzene.com.

Eywa is a global generic pharmaceutical company engaged in research and development, manufacture, marketing, sale, and distribution of generic finished dosage formulations. Learn more at www.eywapharma.com.

Galatea Bio is a biobank intended to improve diagnostic testing and accelerate drug discovery in diverse underserved populations. The company functions as a biosample to bioinformatics platform for powering genomic discovery in understudied populations and identifies patients at risk of suffering severe multi-inflammatory syndromes or infections.  Learn more at www.galatea.bio.

Immuneel is a pioneering clinical stage start-up company leading the change in cell & gene therapies & personalized immunotherapy for patients in India. Headquartered in Bengaluru, Karnataka, India, Immuneel is a research-led, fully integrated cell & gene therapies company committed to bringing breakthrough cancer treatments to India, affordably & build a portfolio of next generation cell therapies. Learn more at www.immuneel.com.

Invetx is a pioneer in creating novel, protein-based animal health therapeutics to transform standards of care in veterinary medicine. The company leverages a best-in-class, fully integrated biotechnology platform for the discovery, development, and manufacturing of veterinary monoclonal antibodies, and is developing a diverse product pipeline addressing chronic and severe diseases in the veterinary species. In July 2024, Invetx was acquired by Dechra Pharmaceuticals Limited (Dechra), a global specialist veterinary pharmaceuticals business. Learn more at www.invetx.com.

Ivenix is dedicated to eliminating infusion-related patient harm, uniquely positioned at the crossroads of healthcare IT and infusion delivery. Ivenix was acquired by Fresenius Kabi in 2022.

Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. For more information, please visit us at www.metsera.com.

OZiva is a plant-based Clean Nutrition Brand. The brand’s core differentiator lies in building a nutrition & fitness ecosystem that combines the best of ancient sciences such as Ayurveda, modern micronutrients, and an instantaneous digital community altogether.  Learn more at www.oziva.in.

Rallybio (NASDAQ: RLYB) is a biopharmaceutical company focused on identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Learn more at www.rallybio.com.